- 765 Allogeneic Tcra/ß Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts https://ash.confex.com/ash/2016/webprogram/Paper97033.html
- 381 Preclinical Evaluation of Allogeneic Anti-Bcma Chimeric Antigen Receptor T Cells with Safety Switch Domains and Lymphodepletion Resistance for the Treatment of Multiple Myeloma https://ash.confex.com/ash/2016/webprogram/Paper90155.html
- 4039 Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) https://ash.confex.com/ash/2016/webprogram/Paper95092.html
In June 2014, Cellectis and Pfizer began collaborating on a joint clinical development program for CAR-T therapies, in the field of oncology, directed at numerous targets selected by Pfizer.Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group. Disclaimer This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.